Valetudo shifts 4.37M Liminatus Pharma shares

Liminatus Pharma insider filing reports an internal share transfer by a major holder.

Rhea-AI Filing Summary

Liminatus Pharma insider filing reports an internal share transfer by a major holder. Valetudo Therapeutics LLC, a ten percent owner associated with CEO and director Chris Kim, transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd. for no payment of consideration.

Valetudo retains voting power over the transferred shares under a voting agreement and continues to hold 1,795,803 shares of Liminatus Pharma common stock of record. Kim may be deemed the beneficial owner through his control of Valetudo but disclaims beneficial ownership beyond his ultimate pecuniary interest.

Insider Trade Summary

Other: 4,373,603 shares

Other 1 txn

Insider Valetudo Therapeutics LLC, Kim Chris

Role 10% Owner | Chief Executive Officer

Type	Security	Shares	Price	Value
Other	Common Stock, par value $0.0001 per share	4,373,603	$0.00	$0.00

Holdings After Transaction: Common Stock, par value $0.0001 per share — 1,795,803 shares (Direct)

Footnotes (2)

1. F1. Consists of 1,795,803 shares of common stock held of record by Valetudo Therapeutics LLC ("Valetudo"). On June 24, 2026, Valetudo transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd and retains voting power over such shares pursuant to a voting agreement. Mr. Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. The business address of Valetudo is 2251 Stern Goodman Street, Suite E, Fullerton, California 92833. Mr. Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein.
2. F2. The reported transaction involves a transfer of securities for which no payment of consideration was received.

Key Figures

Shares transferred: 4,373,603 shares Shares held of record after transaction: 1,795,803 shares Transaction price per share: $0.0000 per share +1 more

4 metrics

Shares transferred 4,373,603 shares Common stock moved from Valetudo to Ewon Comfortech on June 24, 2026

Shares held of record after transaction 1,795,803 shares Common stock held by Valetudo Therapeutics LLC after restructuring

Transaction price per share $0.0000 per share No consideration paid for the 4,373,603-share transfer

Restructuring shares 4,373,603 shares Classified as an "other" restructuring-type transaction (code J)

Key Terms

beneficial owner, voting agreement, pecuniary interest, ten percent owner

4 terms

beneficial owner financial

"may be deemed to be the beneficial owner of, the shares held"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

voting agreement financial

"retains voting power over such shares pursuant to a voting agreement"

A voting agreement is a legally binding pact in which shareholders promise to cast their votes the same way on certain corporate matters, such as electing directors or approving a merger. It matters to investors because it changes who controls company decisions and makes outcomes more predictable—like a group of neighbors agreeing in advance to vote the same way on a community rule, it can strengthen or limit the influence of other shareholders and affect the company’s future direction.

pecuniary interest financial

"disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest"

ten percent owner financial

"Valetudo Therapeutics LLC, a ten percent owner reporting person in the filing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Liminatus Pharma (LIMN) report in this Form 4?

The Form 4 reports Valetudo Therapeutics LLC transferring 4,373,603 Liminatus Pharma common shares to Ewon Comfortech Co., Ltd. for no consideration, while retaining voting power over those shares under a voting agreement and continuing to hold 1,795,803 shares of record.

Who is Valetudo Therapeutics LLC in relation to Liminatus Pharma (LIMN)?

Valetudo Therapeutics LLC is a ten percent owner of Liminatus Pharma. It holds 1,795,803 common shares of record and is controlled by CEO and director Chris Kim, who has voting and dispositive power over shares held by Valetudo through his role as controlling member.

How many Liminatus Pharma (LIMN) shares were transferred and to whom?

Valetudo Therapeutics LLC transferred 4,373,603 Liminatus Pharma common shares to Ewon Comfortech Co., Ltd. The transfer was reported as an "other" transaction with no payment of consideration, and Valetudo retains voting power over those transferred shares via a voting agreement.

Did Valetudo receive any payment for the Liminatus Pharma (LIMN) share transfer?

No payment was received for the transfer. A footnote states the reported transaction involves a transfer of Liminatus Pharma securities for which no consideration was paid, indicating this was a non-cash, internal reallocation rather than a market sale or purchase of shares.

What is Chris Kim’s relationship to the Liminatus Pharma (LIMN) shares held by Valetudo?

Chris Kim is CEO, director and controlling member of Valetudo Therapeutics LLC, giving him voting and dispositive power over its Liminatus Pharma shares. He may be deemed a beneficial owner but disclaims beneficial ownership except to the extent of his ultimate pecuniary interest.

How many Liminatus Pharma (LIMN) shares does Valetudo hold after the reported transaction?

After the reported transaction, Valetudo Therapeutics LLC holds 1,795,803 Liminatus Pharma common shares of record. It also retains voting power over the 4,373,603 transferred shares under a voting agreement, according to the footnote in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 04:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valetudo Therapeutics LLC

(Last) (First) (Middle)

2251 STERN GOODMAN STREET, SUITE E,

(Street)

FULLERTON CALIFORNIA 92833

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Liminatus Pharma, Inc. [ LIMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	06/24/2026		J		4,373,603	D	(2)	1,795,803(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Valetudo Therapeutics LLC

(Last) (First) (Middle)

2251 STERN GOODMAN STREET, SUITE E,

(Street)

FULLERTON CALIFORNIA 92833

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kim Chris

(Last) (First) (Middle)

2251 STERN GOODMAN STREET, SUITE E,

(Street)

FULLERTON CALIFORNIA 92833

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

Explanation of Responses:

1. Consists of 1,795,803 shares of common stock held of record by Valetudo Therapeutics LLC ("Valetudo"). On June 24, 2026, Valetudo transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd and retains voting power over such shares pursuant to a voting agreement. Mr. Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. The business address of Valetudo is 2251 Stern Goodman Street, Suite E, Fullerton, California 92833. Mr. Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein.

2. The reported transaction involves a transfer of securities for which no payment of consideration was received.

	By: /s/ Chris Kim	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)